Cannabinoid type 1 receptor: another arrow in the adipocytes' bow

J Neuroendocrinol. 2008 May:20 Suppl 1:130-8. doi: 10.1111/j.1365-2826.2008.01682.x.

Abstract

The endocannabinoid system has recently emerged as an important modulator of several functions of adipose tissue, including cell proliferation, differentiation and secretion. Here, we will review the effects of cannabinoid type 1 (CB(1)) receptor activation/blockade in adipocytes by summarising the data in the literature since the discovery of the presence of this receptor in adipose tissue. We will also discuss our original data obtained in mouse 3T3-L1 adipocyte cells using WIN55 212, a CB(1)/CB(2) receptor agonist and SR141716 (rimonabant), a specific CB(1) receptor antagonist, respectively, in different experimental settings.

Publication types

  • Review

MeSH terms

  • Adipocytes / metabolism*
  • Adipogenesis / drug effects
  • Adipogenesis / physiology
  • Adipokines / metabolism
  • Adipose Tissue / drug effects
  • Adipose Tissue / metabolism
  • Adipose Tissue / physiology
  • Animals
  • Benzoxazines / pharmacology
  • Cannabinoid Receptor Modulators / metabolism
  • Cannabinoid Receptor Modulators / physiology
  • Cannabinoids / antagonists & inhibitors
  • Cannabinoids / pharmacology
  • Cell Differentiation / drug effects
  • Cell Proliferation / drug effects
  • Humans
  • Lipid Metabolism / drug effects
  • Lipid Metabolism / physiology
  • Morpholines / pharmacology
  • Naphthalenes / pharmacology
  • Piperidines / pharmacology
  • Pyrazoles / pharmacology
  • Receptor, Cannabinoid, CB1 / metabolism
  • Receptor, Cannabinoid, CB1 / physiology*
  • Rimonabant

Substances

  • Adipokines
  • Benzoxazines
  • Cannabinoid Receptor Modulators
  • Cannabinoids
  • Morpholines
  • Naphthalenes
  • Piperidines
  • Pyrazoles
  • Receptor, Cannabinoid, CB1
  • (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone
  • Rimonabant